Evommune (EVMN) & The Competition Head-To-Head Contrast

Evommune (NYSE:EVMN – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Evommune to related companies based on the strength of its earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Valuation & Earnings

This table compares Evommune and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Evommune $13.00 million -$68.87 million -1.84
Evommune Competitors $688.58 million $7.69 million -18.30

Evommune’s competitors have higher revenue and earnings than Evommune. Evommune is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and price targets for Evommune and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evommune 1 4 10 1 2.69
Evommune Competitors 9940 15324 45736 1605 2.54

Evommune presently has a consensus price target of $30.50, suggesting a potential upside of 333.98%. As a group, “Biotechnology” companies have a potential upside of 133.34%. Given Evommune’s stronger consensus rating and higher possible upside, equities analysts plainly believe Evommune is more favorable than its competitors.

Institutional & Insider Ownership

47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 31.1% of Evommune shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Evommune and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evommune N/A -43.53% -40.11%
Evommune Competitors -12,224.75% -204.85% -31.52%

Summary

Evommune beats its competitors on 6 of the 11 factors compared.

About Evommune

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. Founded in 2020, the company focuses on biological pathways involved in inflammation and aims to develop treatments for conditions with significant unmet medical needs. Its pipeline includes EVO756, an oral investigational medicine designed to block MRGPRX2, a receptor involved in mast-cell activation. The candidate is being studied for inflammatory skin disorders, including chronic spontaneous urticaria and atopic dermatitis.

Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.